This Is MS Multiple Sclerosis Knowledge & Support Community

Report: Biogen Idec CEO predicts more brain disorders in Tysabri patients

The CEO of Biogen Idec told investors Tuesday that he expects to see more cases of a rare, fatal brain disorder in patients taking the drug Tysabri, Reuters reported Tuesday.

But James Mullen, the executive, thinks the problems are unlikely to create more regulatory problems for Tysabri, a multiple sclerosis drug pulled temporarily from the market in 2005 thanks to the brain disease.


(hope I am not pissing off Ty users by posting negative articles. I figure knowledge is power...)

(hope I am not pissing off Ty users by posting negative articles. I figure knowledge is power...)

Rainer....what's negative about your posting? It's something that the CEO of Biogen stated and is likely scientific fact. It may not be what some Tysabri users like to hear but it certainly is not "negative."

I'm afraid there is going to be more problems with this drug as time goes by but we'll just have to wait and see as more data becomes available.

Harry